Cargando…
PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response
Idarubicin (IDA), an anthracycline antineoplastic drug, is commonly used in the treatment of acute myeloid leukemia (AML) with reasonable response rates and clinical benefits. However, some patients still relapse, or do not respond, and suffer high fatality rates. Recent studies have shown that over...
Autores principales: | Ke, Bo, Li, Anna, Fu, Huan, Kong, Chunfang, Liu, Tingting, Zhu, Qingqing, Zhang, Yue, Zhang, Zixia, Chen, Chen, Jin, Chenghao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909352/ https://www.ncbi.nlm.nih.gov/pubmed/35130631 http://dx.doi.org/10.3724/abbs.2021011 |
Ejemplares similares
-
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020) -
NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression
por: Bian, Chunjing, et al.
Publicado: (2019) -
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020) -
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
por: Francica, Paola, et al.
Publicado: (2018) -
PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)